172 related articles for article (PubMed ID: 30316985)
21. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Zappia M; Annesi G; Nicoletti G; Arabia G; Annesi F; Messina D; Pugliese P; Spadafora P; Tarantino P; Carrideo S; Civitelli D; De Marco EV; Cirò-Candiano IC; Gambardella A; Quattrone A
Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
Ivanova SA; Alifirova VM; Pozhidaev IV; Freidin MB; Zhukova IA; Osmanova DZ; Zhukova NG; Mironova YA; Tiguntsev VV; Fedorenko OY; Bokhan NA; Wilffert B; Loonen AJM
J Pharm Pharm Sci; 2018; 21(1):340-346. PubMed ID: 30075828
[TBL] [Abstract][Full Text] [Related]
23. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
[TBL] [Abstract][Full Text] [Related]
24. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
Foltynie T; Cheeran B; Williams-Gray CH; Edwards MJ; Schneider SA; Weinberger D; Rothwell JC; Barker RA; Bhatia KP
J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):141-4. PubMed ID: 18977816
[TBL] [Abstract][Full Text] [Related]
25. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
[TBL] [Abstract][Full Text] [Related]
26. Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?
Rieck M; Schumacher-Schuh AF; Callegari-Jacques SM; Altmann V; Schneider Medeiros M; Rieder CR; Hutz MH
Pharmacogenomics; 2015; 16(6):573-82. PubMed ID: 25872644
[TBL] [Abstract][Full Text] [Related]
27. Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
Dwivedi A; Dwivedi N; Kumar A; Singh VK; Pathak A; Chaurasia RN; Mishra VN; Mohanty S; Joshi D
J Geriatr Psychiatry Neurol; 2023 Mar; 36(2):98-106. PubMed ID: 35603896
[TBL] [Abstract][Full Text] [Related]
28. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.
van de Giessen E; de Win MM; Tanck MW; van den Brink W; Baas F; Booij J
J Nucl Med; 2009 Jan; 50(1):45-52. PubMed ID: 19091889
[TBL] [Abstract][Full Text] [Related]
29. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
[TBL] [Abstract][Full Text] [Related]
30. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
31. Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension.
Kim WT; Lee SR; Roh YG; Kim SI; Choi YH; Mun MH; Jeong MS; Koh SS; Leem SH
DNA Cell Biol; 2017 Mar; 36(3):227-236. PubMed ID: 28055236
[TBL] [Abstract][Full Text] [Related]
32. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
Molchadski I; Korczyn AD; Cohen OS; Katzav A; Nitzan Z; Chapman J; Hassin-Baer S
Acta Neurol Scand; 2011 Feb; 123(2):117-21. PubMed ID: 21108621
[TBL] [Abstract][Full Text] [Related]
33. An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
Cai XY; Kong XM; Fang Q; Ning P; Xu YJ; Zhang B; Xue SR
Neurodegener Dis; 2012; 9(1):11-7. PubMed ID: 21876323
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
35. [Association between genetic polymorphism of dopamine transporter gene and susceptibility to Parkinson's disease].
Wang J; Liu Z; Chen B
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):346-8. PubMed ID: 11798784
[TBL] [Abstract][Full Text] [Related]
36. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
37. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
38. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.
Kelada SN; Costa-Mallen P; Checkoway H; Carlson CS; Weller TS; Swanson PD; Franklin GM; Longstreth WT; Afsharinejad Z; Costa LG
Pharmacogenet Genomics; 2005 Sep; 15(9):659-68. PubMed ID: 16041244
[TBL] [Abstract][Full Text] [Related]
39. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
Rieck M; Schumacher-Schuh AF; Altmann V; Callegari-Jacques SM; Rieder CRM; Hutz MH
Pharmacogenomics J; 2018 Jan; 18(1):196-200. PubMed ID: 27779245
[TBL] [Abstract][Full Text] [Related]
40. Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.
Santos-Lobato BL; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
Nitric Oxide; 2018 Apr; 74():86-90. PubMed ID: 28602747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
